intetumumab + dacarbazine

**Intetumumab + dacarbazine** is a combination regimen investigated for the treatment of advanced (stage IV) melanoma. Intetumumab (CNTO 95) is a fully human monoclonal antibody targeting all members of the alpha-v integrin family (including αvβ1, αvβ3, αvβ5, αvβ6, αvβ8), which play key roles in angiogenesis and tumor growth. It exerts anti-tumor activity by blocking integrin-mediated cell adhesion, migration, proliferation, and inducing apoptosis in both tumor and endothelial cells[1][2][4]. Dacarbazine is a well-established alkylating agent for melanoma, acting mainly through DNA damage and cytotoxicity. The combination was studied to evaluate possible synergistic anti-tumor effects. Phase II clinical trials showed that the combination produced a nonsignificant improvement in overall survival compared to dacarbazine alone, and did not significantly alter progression-free survival or objective response rates for metastatic melanoma. Intetumumab + dacarbazine was generally well-tolerated, with common adverse events including headache, fatigue, nausea, vomiting, fever, chills, and transient, self-limiting ocular inflammation. The combination did not increase myelosuppression above dacarbazine monotherapy, and no intetumumab-related deaths or severe laboratory abnormalities were reported[1][4].